Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.

ABSTRACT:

SUBMITTER: Bomben R 

PROVIDER: S-EPMC10079531 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature